Malignant Mixed Mesodermal (Mullerian) Tumor

subtype

Identifier: CI-CAN-00001143
Entity page: /cancer/malignant-mixed-mesodermal-mullerian-tumor ↗
Edges: 34

Neighbours: 4 genes14 drugs10 trials
Drawn: 28 of 28 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Malignant Mixed Mesodermal (Mullerian) Tumor altered in cohorts of …ALTERED_INderived4 of 4
← altered in cohorts of	TP53 52 / 57 cases (91 %) · ssm · ucs_tcga · largest of 3 cohorts	—	—	Uterine Malignant Mixed Mesodermal (Mullerian) Tumor	3	Observed	cbioportal	graph →
← altered in cohorts of	FBXW7 22 / 57 cases (39 %) · ssm · ucs_tcga · largest of 3 cohorts

Malignant Mixed Mesodermal (Mullerian) Tumor investigated in trials for …INVESTIGATED_IN_TRIALSderived14 of 14
→ investigated in trials for	Bevacizumabmonoclonal antibody 6 trials (2 active) · roll-up of the cancer and its descendants	—	—	Malignant Mixed Mesodermal (Mullerian) Tumor	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Paclitaxelsmall molecule 4 trials (1 active) · roll-up of the cancer and its descendants	—	—	Malignant Mixed Mesodermal (Mullerian) Tumor	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Malignant Mixed Mesodermal (Mullerian) Tumor	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Doxorubicinsmall molecule 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Malignant Mixed Mesodermal (Mullerian) Tumor	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Gemcitabinesmall molecule 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Malignant Mixed Mesodermal (Mullerian) Tumor	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Olaparibsmall molecule 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Malignant Mixed Mesodermal (Mullerian) Tumor	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 2 trials (2 active) · roll-up of the cancer and its descendants	—	—	Malignant Mixed Mesodermal (Mullerian) Tumor	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Adavosertibsmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Malignant Mixed Mesodermal (Mullerian) Tumor	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Bendamustinesmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Malignant Mixed Mesodermal (Mullerian) Tumor	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Malignant Mixed Mesodermal (Mullerian) Tumor	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Malignant Mixed Mesodermal (Mullerian) Tumor	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Nab-paclitaxel 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Malignant Mixed Mesodermal (Mullerian) Tumor	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Topotecansmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Malignant Mixed Mesodermal (Mullerian) Tumor	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Veliparibsmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Malignant Mixed Mesodermal (Mullerian) Tumor	1	Observed	clinicaltrials	graph →

Malignant Mixed Mesodermal (Mullerian) Tumor investigated in trials for …INVESTIGATED_IN_TRIALSderived14 of 14

→ investigated in trials for

Bevacizumabmonoclonal antibody

6 trials (2 active) · roll-up of the cancer and its descendants

—

Malignant Mixed Mesodermal (Mullerian) Tumor

Observed

Malignant Mixed Mesodermal (Mullerian) Tumor studied in …STUDIED_INderived10 of 16show all (up to 200)
→ studied in	NCT05256225Phase 3 · recruiting Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma · condition mapped ONTOLOGY_EXACT · 16 trials mapped (9 active)	—	—	Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT05920798Phase 1/Phase 2 · active not recruiting Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer · condition mapped ALIAS · 16 trials mapped (9 active)	—	—	Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT02101775Phase 2 · active not recruiting Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 16 trials mapped (9 active)	—	—	Ovarian Malignant Mixed Mesodermal (Mullerian) Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT06580314Phase 3 · recruiting Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 16 trials mapped (9 active)	—	—	Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT04092270Phase 1 · active not recruiting A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 16 trials mapped (9 active)	—	—	Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT01737619NA · active not recruiting PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 16 trials mapped (9 active)	—	—	Malignant Mixed Mesodermal (Mullerian) Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT04919629Phase 2 · recruiting APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion · condition mapped ALIAS · 16 trials mapped (9 active)	—	—	Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT06483048Phase 1 · recruiting MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer · condition mapped CURATED_BROADER · 16 trials mapped (9 active)	—	—	Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT05494580Phase 1/Phase 2 · completed Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer · condition mapped ALIAS · 16 trials mapped (9 active)	—	—	Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT02364713Phase 2 · terminated MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer · condition mapped ALIAS · 16 trials mapped (9 active)	—	—	Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains